Kadmon

+$0.02 (+0.21%) As of 11:00 PM UTC pre-market

Why Robinhood?

You can watch Kadmon and buy or sell other stocks, options, and ETFs commission-free!

About KDMN

Kadmon Corporation, a biopharmaceutical company, offers products and services for the treatment and management of hepatitis C. Its products include Ribasphere RibaPak (ribavirin, USP) tablets, which help to reduce pill burden while providing patients with treatment that is biologically equivalent to other ribavirin medications; INFERGEN (interferon alfacon-1) to treat chronic hepatitis C in patients 18 years of age or older with compensated liver disease; Ribasphere (ribavirin, USP) tablets and capsules, which are antiviral medications for use in combination with other drugs for the treatment of chronic hepatitis C; and KD020, a reversible tyrosine kinase inhibitor that targets EGFR, HER2, VEGFR 2/3, and Src in autosomal dominant polycystic kidney disease (PKD).

CEO
Gustavo Pesquin; Harlan W. Waksal, MD
Employees
—
Headquarters
New York, New York
Founded
2010

KDMN Key Statistics

Market cap
1.68B
Price-Earnings ratio
—
Dividend yield
—
Average volume
4.56M
High today
—
Low today
—
Open price
—
Volume
0.00
52 Week high
$9.50
52 Week low
$3.36

KDMN Earnings

-$0.20
-$0.13
-$0.07
$0.00
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Estimated
-$0.20 per share
Actual
-$0.20 per share
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure